Results published in the Clinical Journal of Oncology from a Phase 2 study by Makker et al. has shown that lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma. The combination therapy was also shown to have a manageable toxicity profile. (Title of paper: Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer, DOI: 10.1200/JCO.19.02627).
Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. LENVIMA is an orally available kinase inhibitor discovered by Eisai, whilst KEYTRUDA is Merck’s anti-PD-1 therapy.